New drug shows promise for rare liver disease in small trial

NCT ID NCT05543174

First seen Jan 31, 2026 · Last updated May 14, 2026 · Updated 13 times

Summary

This study tested a drug called TAK-625 in 7 Japanese people with Alagille Syndrome, a rare liver condition. The goal was to see if the drug could improve symptoms like itching and lower bile acid levels. Participants took the drug for up to 34 months and had regular clinic visits to check safety and how the drug worked in their bodies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALAGILLE SYNDROME (ALGS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, Japan

  • Kindai University Nara Hospital

    Ikoma, Nara, Japan

  • Kyoto University Hospital

    Kyoto, Japan

  • Miyagi Children's Hospital

    Sendai, Miyagi, Japan

  • Osaka University Hospital

    Suita, Osaka, Japan

  • Saitama Prefectural Children's Medical Center

    Saitama, Japan

  • University of Tsukuba Hospital

    Tsukuba, Ibaraki, Japan

  • Yokohamashi Tobu Hospital

    Yokohama, Kanagawa, Japan

Conditions

Explore the condition pages connected to this study.